New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:06 EDTEXASExact Sciences announces DeeP-C study results published
Exact Sciences announced that results from its DeeP-C clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3 print issue. The company said, "In our clinical study, the data show that Cologuard, the multi-target stool-based DNA test, is highly sensitive in detecting colorectal cancer and higher risk pre-cancerous polyps in a large, diverse average-risk patient population and has the potential to be an important screening tool.” The Exact Sciences Cologuard screening test is an investigational device currently under review by the U.S. Food and Drug Administration and is not available for sale in the U.S. The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27.
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
09:32 EDTEXASExact Sciences management to meet with Roth Capital
Meeting to be held in Boston on September 3 hosted by Roth Capital.
08:00 EDTEXASExact Sciences price target raised to $28 from $22 at JMP Securities
JMP Securities increased its price target on Exact Sciences as the firm, after conducting channel checks, estimates that ColoGuard will sell for $375. The firm continues to recommend buying shares of the stock.
August 26, 2014
07:46 EDTEXASExact Sciences price target raised to $23 from $21 at Canaccord
Canaccord raised its price target on Exact Sciences to $23 from $21 following yesterday's announcement the Mayo Clinic will adopt Cologuard. The firm believes there is the potential for additional healthcare systems to come on board as the publicity raises awareness among primary care doctors. Canaccord keeps its Buy rating on shares of Exact Sciences.
August 25, 2014
11:26 EDTEXASOptions with increasing implied volatility: EXAS FTR PSEC
Subscribe for More Information
August 22, 2014
13:31 EDTEXASExact Sciences test not reimbursed by Aetna, says Maxim
Subscribe for More Information
10:07 EDTEXASOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
August 20, 2014
11:47 EDTEXASOptions with increasing implied volatilit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use